6583results about "Lyophilised delivery" patented technology

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry 10 powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The invention relates to the technical field of biology, in particular to multifunctional belly-expanding hippocampal peptide as well as a preparation method and application thereof. Comprising a polypeptide with an amino acid sequence as shown in SEQ ID NO.1. The hippocampus antioxidative peptide is prepared by adopting an ultrahigh pressure pretreatment and enzymolysis technology, the adopted extraction process is simple in route, and the time and the production cost are effectively saved; an animal model is utilized to prove the anti-oxidation effect and the effect of improving male reproductive disorder and testis injury of the multifunctional belly-expanding hippocampal peptide; and on the basis, a novel peptide fragment with high activity, no toxicity and no sensitization is obtained.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

A compound bacterial powder preparation, and a preparation method therefor and the use thereof. The compound bacterial powder preparation comprises Bifidobacterium animalis, Lactiplantibacillus plantarum and Bacillus coagulans, wherein the deposit number of the Bifidobacterium animalis strain is CGMCC No.25681. The compound bacterial powder preparation can stimulate macrophage RAW264.7 of a mouse to generate cell factors TNF-α and IL-6, thereby enhancing immunity; can significantly enhance the cellular immune function, the humoral immune function and the mononuclear-macrophage function of a mouse, and has the function of enhancing immunity; and can increase the ink propelling rate and has the functional potential of relaxing the bowels.

Building on U.S. Provisional Patent Application No. 63 / 693,803, paragraphs for 2D-to-3D conversion and [0023]-[0024] for secure content verification, the Matrix 3D AI Polygon Mesh Hash Key System revolutionizes transforming 2D content into secure, interactive 3D AR / VR assets. Integrating AI and LiDAR, it enables real-time 3D mesh generation with precise geospatial anchoring. Users can reshape 3D content instantly via natural language commands, enhancing interactivity. Quantum-resistant encryption, using AES-256 and CRYSTALS-Kyber, ensures robust asset security. The system excels in gaming, surveillance, content verification, military operations, space exploration, deepfake detection, and pharmaceutical research, offering unmatched precision and scalability. Its multi-stage rendering pipeline, powered by distributed AI-driven bots, supports efficient real-time 3D mesh generation, achieving 95% accuracy and 1 cm resolution. This AR / VR technology advancement transforms industries with scalable, secure solutions for interactive 3D content creation and management, setting a new standard for precision and versatility.

In some embodiments, provided herein is a composition comprising cryopreserved anti-cancer drug-loaded platelet composition, and a process for preparing the same, in illustrative embodiments, cryopreserved anti-cancer drug-loaded platelet composition can be stored at a temperature in a range of −10° C. to −30° C. for at least 1 month. The anti-cancer drug-loaded platelets in the composition can be platelet derivatives. In some embodiments provided herein are methods of preparing anti-cancer drug loaded platelet derivatives, or cryopreserved anti-cancer drug-loaded platelets, comprising: incubating platelets with an anti-cancer drug, and with a loading buffer comprising a monosaccharide and / or a disaccharide, to form anti-cancer drug-loaded platelets, and lyophilizing or freezing the anti-cancer drug-loaded platelets, to form anti-cancer drug loaded platelet derivatives, or cryopreserved anti-cancer drug-loaded platelets, respectively. In some embodiments, provided herein are methods of administering anti-cancer drug loaded platelet derivatives and cryopreserved platelets.

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.

The invention provides BiTE for tumor targeted immunotherapy and a preparation method and application, and relates to the technical field of biological pharmacy, the BiTE is obtained by coupling a nano antibody and fusion protein, the C terminal of the nano antibody contains an amino acid sequence SEQ ID No.3, and the BiTE has the function of targeting a human epidermal growth factor receptor on tumor cells; the fusion protein also targets a CD3 receptor on a T cell, activates the T cell, connects the T cell with a tumor cell in time and space, activates the T cell, secretes perforin and granzyme B to kill the tumor cell, and plays a role in targeted immunotherapy. The isopeptide bond is used for coupling the nano antibody and the fusion protein, coupling can be completed within 15 min, the coupling efficiency is 100%, and the in-vivo half-life period of the nano antibody can be prolonged by 6 times.

The present invention provides a formulation method for encapsulating a negatively charged or hydrophobic target agent by lipid nanoparticles (LNPs). The formulation method comprises impinging an organic phase solution having an ionizable or cationic lipid and an aqueous phase solution. The target agent may be in the organic or aqueous phase solution. The formulation method further comprises self-assembling LNPs, each of which comprises a lipid membrane formed having the ionizable or cationic lipid, whereby the target agent is entrapped by the ionizable or cationic lipid and encapsulated by the LNPs. Also provided is an LNP comprising two or more negatively charged or hydrophobic target agents entrapped by an ionizable or cationic lipid and encapsulated by the LNP. Further provided are the uses of LNPs for intracellular delivery and for stimulating an immune response.

The invention discloses a polymer drug-loaded particle for targeted adhesion to an intestinal inflammation area and a preparation method and application thereof.The method includes the steps that degradable polymer drug-loaded particles are subjected to surface modification through polycations and then added into a monomer solution of an adhesion layer, particle surface in-situ polymerization is initiated through ultraviolet irradiation, and a PAN adhesion layer is formed; the adhesion layer modified polymer drug-loaded particles are obtained. Wherein the polycation is used as a middle layer, so that the PAN adhesion layer can be successfully modified. Carboxyl in the adhesion layer enables the particles to present negative charges, meanwhile, succinimide ester can react with amino naturally existing on the surface of inflammatory intestinal tissue to generate an amide covalent bond, and finally targeted adhesion of the intestinal inflammation part is achieved. According to the adhesion strategy, the PAN can be effectively applied to the micro-nano-scale drug-loaded particles so as to enhance the adhesion of the micro-nano-scale drug-loaded particles in an intestinal tract damaged area, and a brand new thought is provided for treating inflammatory intestinal tracts.

The invention relates to an arteannuic acid derivative as well as a preparation method and application thereof, the arteannuic acid derivative comprises water-soluble organic salt formed by reaction of arteannuic acid or dihydroarteannuic acid and small molecular alkaline organic matter, or water-soluble complex formed by reaction of arteannuic acid or dihydroarteannuic acid and small molecular peptide, or water-soluble complex formed by reaction of arteannuic acid or dihydroarteannuic acid and small molecular peptide. The arteannuic acid or the dihydroarteannuic acid reacts with an alkaline metal compound to form a water-soluble salt. The arteannuic acid derivative provided by the invention solves the problem that arteannuic acid and dihydroarteannuic acid are insoluble in water, has the biological activity of whitening, anti-inflammatory and anti-tumor, and has good research and development prospects.

The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

The invention belongs to the field of biological medicine, and particularly relates to application of recombinant III-type humanized collagen in an injection. The invention provides an injection, the injection comprises recombinant III-type humanized collagen, the amino acid sequence of the recombinant III-type humanized collagen comprises n repetitions of the sequence as shown in SEQ ID NO.1, n is an integer greater than or equal to 1, and when n is an integer greater than or equal to 2, the repetitions are directly connected; moreover, when the injection is applied in one application period, the total application amount of the recombinant III-type humanized collagen is less than or equal to 3640 mg / kg. The recombinant III-type humanized collagen has high-dose injection safety, and can be applied in a single high-dose manner or continuously applied to realize high-dose application in a total amount level.

The invention belongs to the technical field of medicines, and particularly relates to a pyruvate-containing composite preparation as well as a preparation method and application thereof. The composite preparation containing pyruvate is prepared from the following components in percentage by mass: 0.02 to 0.04 percent of a compound A, 0.05 to 0.1 percent of pyruvate, 0.2 to 2 percent of sodium dihydrogen phosphate, 0.2 to 2 percent of disodium hydrogen phosphate, 0.7 to 0.9 percent of sodium chloride and the balance of water for injection, the structural formula of the compound A is as follows: # imgabs0 #. The compound A and pyruvate in the compound preparation interact with each other, so that lung inflammatory response can be inhibited, the level of inflammatory factors can be reduced, and lung edema can be relieved.

The invention discloses a preparation method of a zinc-dihydromyricetin nano-enzyme and application of the zinc-dihydromyricetin nano-enzyme in preparation of drugs for promoting healing of diabetic wounds, and the zinc-dihydromyricetin metal polyphenol nano-enzyme (Zn-DHM) is obtained by coordinating a metal element zinc (Zn) and a natural product dihydromyricetin (DHM) through a one-step method by taking PVP as a surfactant. The Zn-DHM nano-enzyme prepared by the invention has antioxidant property and cell proliferation and migration promoting ability, and can maintain metabolism and immune homeostasis of diabetic wounds, so that the Zn-DHM nano-enzyme can accelerate early healing of the diabetic wounds.

The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating ovarian reserve hypofunction, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of radix paeoniae alba, 6 to 10 parts of radix bupleuri, 10 to 15 parts of radix rehmanniae preparata, 15 to 30 parts of stir-fried rhizoma dioscoreae, 12 to 20 parts of semen cuscutae, 10 to 12 parts of radix angelicae sinensis, 10 to 15 parts of poria cocos, 12 to 25 parts of fructus ligustri lucidi, 10 to 15 parts of radix salviae miltiorrhizae, 10 to 15 parts of fructus corni and 10 to 15 parts of radix morindae officinalis. The traditional Chinese medicine composition can obviously reduce the level of follicle-stimulating hormone (FSH) of cis-platinum model mice, increase estradiol (E2), increase the number of follicles at all levels, especially the number of primordial follicles, and reduce the number of atresia follicles; the ovarian function of naturally aged mice can be improved, FSH (follicle stimulating hormone) is reduced, anti-mullerian hormone (AMH) and E2 are increased, and the quantity of follicles at all levels, especially the quantity of corpus luteum, primordial follicles and anterior sinus follicles, is increased; therefore, the composition disclosed by the invention has an obvious protection effect on the hypoovarian reserve function.

The invention relates to a water-soluble carbon chain substance for adjusting transmembrane transport and fluidity of a cell membrane, and preparation and application thereof. The water-soluble carbon chain substance comprises a carbon chain originally having certain water solubility, and the structure of the water-soluble carbon chain substance comprises at least one or more hydrophobic carbon chain parts and one or more hydrophilic groups or residues; the hydrophobic carbon chain part is coupled with water-soluble molecules to form a high-hydrophilicity compound; the water-soluble carbon chain can be used for preventing and treating infections including viruses, bacteria and fungi; anti-aging; the occurrence of neurodegenerative diseases such as Alzheimer's disease is prevented and reduced; by reducing the non-specific phagocytosis of the nano-drug by cells, the effect of the nano-drug on a target focus is enhanced.

The present disclosure provides STING agonists and compositions, formulations, and methods for treating diseases or conditions (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) using STING agonists or compositions thereof.